Put away the flamethrow­er Mr. Pres­i­dent. We come in peace and pros­per­i­ty.

End­points as­sess­es the big bio­phar­ma sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

The lat­est wacky com­pen­sa­tion deals un­der­score just how im­por­tant this is­sue is

Valeant may be one of the most dys­func­tion­al com­pa­nies in bio­phar­ma, but why should that get in the way of a big pay­day for the CEO? We learned this week that Joseph Pa­pa will get $62.7 mil­lion in pay for last year — a year in which Valeant’s busi­ness mod­el ceased func­tion­ing.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.